Home → Research News → Ask-the-Expert Conferences: Research News → June 2008: Updates from the 2008 ASCO Annual Meeting → Link between LCIS and ILC? Okay to decline tamoxifen?

Link between LCIS and ILC? Okay to decline tamoxifen?

Page last modified on: August 19, 2008

Question from Jane6: What is the current thinking on LCIS as a precursor to invasive lobular carcinoma? What is the best treatment for LCIS other than vigilance? Is it appropriate for premenopausal women with a weak family history to decline tamoxifen?: Answer —Carol Kaplan, M.D.: LCIS is still considered a risk factor for development of breast cancer. There is some preliminary research that questions the link between LCIS and invasive lobular carcinoma. However, we have been unable to definitively demonstrate that LCIS has a natural history that leads to invasive cancer directly. Taking tamoxifen is a personal decision, and as long as you feel you have been informed of its particular benefits in breast cancer risk reduction, you can choose close surveillance, including annual MRI and mammography in place of tamoxifen.

On Wednesday, June 18, 2008 our Ask-the-Expert Online Conference was called Updates from the 2008 ASCO Annual Meeting. Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answered your questions about the latest research advances on screening, treatment, side effects, and more.

The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Email Updates

Stay informed about current research, online events, and more.

Meet the Experts

Generosa Grana, M.D., F.A.C.P. is the director of the Cooper Cancer Institute and heads the division of hematology/medical oncology at Cooper University Hospital.

Carol Kaplan, M.D. is an assistant professor of clinical medicine in the Rena Rowan Breast Center at the Hospital of the University of Pennsylvania. Her work revolves around the clinical care of breast cancer patients, as well as teaching medical students and house staff.